GlassScriptPhysician profile
Paul E Fagan
NPI 1336437367
$3,469.61
in general payments reported to CMS, 2019-2025
24 companies · $548 in 2025
The $548 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $884 · 2022: $488 · 2023: $723 · 2024: $827 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,097.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $878.92 | 2021-2025 | Relistor, Trulance |
| Collegium Pharmaceutical, INC. | $640.46 | 2022-2025 | Xtampza, Belbuca |
| Arbor Pharmaceuticals, INC. | $272.80 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $257.27 | 2023-2025 | Horizant, Horizant |
| Scilex Pharmaceuticals INC. | $190.83 | 2021-2024 | Ztlido |
| Idorsia Pharmaceuticals US INC | $178.87 | 2023-2024 | Quviviq |
| Virtus Pharmaceuticals LLC | $141.99 | 2021-2025 | Levorphanol Tartrate |
| Almatica Pharma LLC | $131.76 | 2021-2023 | Gralise |
| Pfizer INC. | $124.67 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $69.33 | 2023 | Belsomra |
| Forte Bio-Pharma LLC | $66.98 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Abbvie INC. | $64.40 | 2023-2024 | |
| Redhill Biopharma INC. | $63.45 | 2021 | |
| Biodelivery Sciences International, INC. | $62.37 | 2021 | |
| Saluda Medical Americas, INC. | $56.85 | 2025 | Evoke |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $53.99 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $52.77 | 2022-2024 | Kloxxado |
| Indivior INC. | $44.08 | 2021 | |
| Boston Scientific Corporation | $39.79 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Averitas Pharma INC. | $18.58 | 2023 | Qutenza |
| Eisai INC. | $17.67 | 2021 | |
| Mml US, INC. | $14.98 | 2023 | Reactiv8 |
| Valinor Pharma, LLC | $13.86 | 2025 | Movantik |
| Grt US Holding, INC. | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Fagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.